Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q2 2024 · 10-Q
Revenue$1.62M$1.62M+455.7% vs Q2 2023 Net Income-$53.43M-$53.43MN/M vs Q2 2023 EPS Diluted-$0.17-$0.17N/M vs Q2 2023 Operating Income-$55,354,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$48,790,000N/M Margins · derivedOperating margin-3423.3%+11779.5 pt vs Q2 2023
Net margin-3304.2%+12126.7 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 2, 2024 · 33 d after period end